β, β-Dimethylacrylshikonin

β, β-Dimethylacrylshikonin (Isoarnebin I) is a naphthoquinone derivative that can be isolated from Lithospermum erythrorhizon Sieb. et Zucc. β, β-Dimethylacrylshikonin promotes angiogenesis by inducing eNOS, VEGF and HIF-1α expression through the PI3K-dependent pathway. β, β-Dimethylacrylshikonin inhibits Notch-1 activation. β, β-Dimethylacrylshikonin inhibtis tumor cell proliferation, induces tumor cell apoptosis, and inhibits tumor growth[1][2][3][4].

Product Specifications

CAS Number

[24502-79-2]

Product Name Alternative

Isoarnebin I

UNSPSC

12352005

Hazard Statement

H302, H319, H332, H372, H400

Target

Apoptosis; Bcl-2 Family; HIF/HIF Prolyl-Hydroxylase; NO Synthase; Notch

Type

Natural Products

Related Pathways

Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease; Neuronal Signaling; Stem Cell/Wnt

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/beta-beta-dimethylacrylshikonin.html

Purity

99.30

Solubility

DMSO : 12.5 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C1C2=C(O)C=CC(O)=C2C(C=C1[C@@H](C/C=C(C)/C)OC(/C=C(C)/C)=O)=O

Molecular Formula

C21H22O6

Molecular Weight

370.40

Precautions

H302, H319, H332, H372, H400

References & Citations

[1]Zeng Z, et al. Arnebin-1 promotes angiogenesis by inducing eNOS, VEGF and HIF-1α expression through the PI3K-dependent pathway. Int J Mol Med. 2015 Sep;36 (3) :685-97.|[2]Sidhu GS, et al. Arnebin-1 accelerates normal and hydrocortisone-induced impaired wound healing. J Invest Dermatol. 1999 Nov;113 (5) :773-81.|[3]Wu Z, et al. β, β-Dimethylacrylshikonin potentiates paclitaxel activity, suppresses immune evasion and triple negative breast cancer progression via STAT3Y705 phosphorylation inhibition based on network pharmacology and transcriptomics analysis. Phytomedicine. 2023 Jun;114:154769. |[4]Zhen-Jun S, et al. β, β-Dimethylacrylshikonin exerts antitumor activity via Notch-1 signaling pathway in vitro and in vivo. Biochem Pharmacol. 2012 Aug 15;84 (4) :507-12.